12:25 AM EDT, 10/20/2026 (MT Newswires) -- MaaT Pharma (MAAT.PA) received positive feedback from the US Food and Drug Administration on the development of its MaaT034 microbiome therapy for solid tumors, including non-small cell lung cancer, melanoma, and renal cell carcinoma. The regulator indicated that the biotechnology company's proposed science- and risk-based development strategy was appropriate and that no additional nonclinical safety studies were required, according to a Monday release. MaaT Pharma plans further discussions with the FDA on its clinical development strategy and could launch a first-in-human study in late 2027, subject to regulatory approvals and funding.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.